scholarly journals Renal Cell Carcinoma Metastatic to the Scalp

Rare Tumors ◽  
2016 ◽  
Vol 8 (4) ◽  
pp. 139-141 ◽  
Author(s):  
Mounir Errami ◽  
Vitali Margulis ◽  
Sergio Huerta
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Natural History ◽  
Bone Metastases ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Metastatic Lesions ◽  
History Of ◽  
Rare Site ◽  
The Brain

Because of the asymptomatic natural history of renal cell carcinoma (RCC), by the time a diagnosis is made, metastatic disease is present in about one third of the cases. Thus, the overall survival of patients with RCC remains poor. Ultimately up to 50% of patients with RCC will develop metastases. Metastatic lesions from RCC are usually observed in the lungs, liver or bone. Metastases to the brain or the skin from RCC are rare. Here we present a patient diagnosed with RCC, found to have no evidence of metastases at the time of nephrectomy, who presented two years later with metastases to the scalp. We review the literature of patients with this rare site of metastasis and outline the overall prognosis of this lesion compared to other site of metastases from RCC.

Comparison of simultaneous high dose stereotactic radiotherapy with normofractionated radiotherapy in patients with metastatic renal cell carcinoma under systemic therapy.

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 467-467 ◽  
Author(s):  
Michael D. Staehler ◽  
Behr Lisa ◽  
Philipp Nuhn ◽  
Boris Schlenker ◽  
Ralf Wilkowski
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Radiation Therapy ◽  
Cell Carcinoma ◽  
Systemic Therapy ◽  
Renal Cell ◽  
High Dose ◽  
Metastatic Lesions ◽  
Conventional Radiation ◽  
Conventional Radiation Therapy

467 Background: Conventional radiation therapy (RT) is considered ineffective in metastatic renal cell carcinoma (mRCC). There are data suggesting that this might be related to low doses per fraction and that higher doses could be more effective. We introduced hypofracationated high-dose radiation therapy in patients with an indication for radiotherapy an retrospectively compared the results to patients with a conventional radiation therapy. Methods: We identified 97 pts with mRCC and an indication for radiotherapy of metastatic lesions between 2007 and 2013. All pts underwent simultaneous systemic therapy based on targeted agents and systemic therapy. 83 pts had a hypofractionated high dose stereotactic radiation (HDRT) (5 Gy per fraction, 3 fractions per week, total 45 Gy) while 14 pts underwent conventional normo-fractionated radiotherapy (NDR) (1.8 Gy per fraction) as described elsewhere. Results: Median age was 64.1 years (27-86). 189 metastatic lesions were irradiated. 64% of the pts had clear cell histology, with 14% harboring papillary RCC type II and 11% other subentities. Median overall survival was significantly longer for pts after HDRT was 9.4 months (+/-9.4 months) and 4.5 months (+/- 3.4 months) after NDR (p=0.01). The multivariate cox regression analysis revealed the MSKCC risk score, HDR therapy and the disease free survival as positive predictors for survival. No grade III toxicities were found, with 24% of the patients experiencing grade 1 or 2 side effects, mainly diarrhea and fatigue. Conclusions: In mRCC HDRT with simultaneous systemic therapy is related to a better overall survival than NRT. HDRT in combination with targeted therapy should be regarded the standard of care if RT is indicated.

THE CHANGING NATURAL HISTORY OF RENAL CELL CARCINOMA

2001 ◽  
pp. 1611-1623 ◽  
Author(s):  
ALLAN J. PANTUCK ◽  
AMNON ZISMAN ◽  
ARIE S. BELLDEGRUN
Keyword(s):  
Renal Cell Carcinoma ◽  
Natural History ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
History Of

NATURAL HISTORY OF SMALL RENAL CELL CARCINOMA: EVALUATION OF GROWTH RATE, HISTOLOGICAL GRADE, CELL PROLIFERATION AND APOPTOSIS

2004 ◽  
Vol 172 (3) ◽  
pp. 863-866 ◽  
Author(s):  
MASANORI KATO ◽  
TAKASHI SUZUKI ◽  
YASUYOSHI SUZUKI ◽  
YOSHIO TERASAWA ◽  
HIRONOBU SASANO ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Growth Rate ◽  
Cell Proliferation ◽  
Natural History ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Histological Grade ◽  
Proliferation And Apoptosis ◽  
History Of

scholarly journals 1715: Enhancing Renal Lesions in Patients with Prior Normal Abdominal Imaging: Insight into the Natural History of Renal Cell Carcinoma

2006 ◽  
Vol 175 (4S) ◽  
pp. 551-551
Author(s):  
Paul L. Crispen ◽  
Aldiana Soljic ◽  
Richard E. Greenberg ◽  
David Y.T. Chen ◽  
Robert G. Uzzo
Keyword(s):  
Renal Cell Carcinoma ◽  
Natural History ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Abdominal Imaging ◽  
Renal Lesions ◽  
History Of ◽  
Insight Into

scholarly journals Prolonged natural history of a cystic renal cell carcinoma: A case report

2020 ◽  
Vol 36 (4) ◽  
pp. 315
Author(s):  
RavimohanS Mavuduru ◽  
MukeshKumar Gupta ◽  
Pawan Kaundal ◽  
GirdharS Bora ◽  
Ujjwal Gorsi
Keyword(s):  
Renal Cell Carcinoma ◽  
Case Report ◽  
Natural History ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Cystic Renal Cell Carcinoma ◽  
History Of

The impact of metastasis location on overall survival among patients with renal cell carcinoma.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 621-621
Author(s):  
Devin Patel ◽  
Fady Ghali ◽  
Margaret Meagher ◽  
Margaret Meagher ◽  
Aaron Bradshaw ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Bone Metastases ◽  
Cell Carcinoma ◽  
Metastatic Disease ◽  
Renal Cell ◽  
Lung Metastases ◽  
Univariate Analysis ◽  
The Impact ◽  
Disease Location

621 Background: Current staging guidelines define all patients with metastatic renal cell carcinoma (RCC) as a singular group. We sought to compare the impact of metastatic disease location on overall survival (OS) in patients with RCC. Methods: We queried our institutional database of consecutive patients with metastatic RCC. A confirmatory analysis was performed using the National Cancer Database (NCDB) for cases between 2010 to 2015. Only cases from which all metastatic disease location was known were used. Patients were grouped into having brain or bone metastases, liver or lung metastases or other metastases. From our institutional database, we performed a univariate analysis to determine the impact of metastasis location on OS. From the NCDB, univariable and multivariable Cox proportional hazards and Kaplan-Meier survival analysis with log-rank testing was performed. Multivariable models were adjusted for age, comorbidity, race, gender, and treatment with either palliative care, chemotherapy or immunotherapy. Results: A total of 95 patients were analyzed from our institutional database, with 30 (31.9%) having brain/bone metastases, 20 (21.3%) having lung/liver metastases, and 44 (46.8%) having other site metastases. On univariate analysis, patients with brain/bone metastases had significantly worse OS (HR 1.87; 95% CI 1.01-3.47). However, no significant difference was seen in patients with liver/lung metastases (HR 1.44; 95% CI 0.64-3.27). A total of 25,528 patients met inclusion for our NCDB analysis, of which 12,119 (47.5%) had brain/bone metastases, 10,004 (39.2%) had liver/lung metastases, and 3,405 (13.3%) had other site metastases. On univariate analysis, patients with lung/liver (HR 1.46; 95% CI 1.38-1.53) and patients with bone/brain (HR 1.69; 95% CI 1.60-1.77) had progressively worse OS with non-overlapping confidence intervals. Multivariable analysis again showed that patients with lung/liver disease (HR 1.51; 95% CI 1.43-1.59) and brain/bone disease (HR 1.66; 95% CI 1.60-1.75) had progressively worse OS. Conclusions: Our results highlight the heterogeneity of patients with metastatic renal cell carcinoma. Location of metastatic disease may drive differences in survival.

A Case of Renal Cell Carcinoma with a Natural History of 13 Years

2004 ◽  
Vol 72 (2) ◽  
pp. 171-173
Author(s):  
Faruk Özcan ◽  
Isin Kilicaslan
Keyword(s):  
Renal Cell Carcinoma ◽  
Natural History ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
History Of
Sign in / Sign up

Export Citation Format

Share Document